Valneva outlines $145M-$160M 2026 revenue guidance while Pfizer targets Lyme decisions within 12 months

PLX: Elfabrio Estimates Up

By John Vandermosten, CFANYSE: PLXREAD THE FULL PLX RESEARCH REPORTSecond Quarter 2026 Financial and Operational ReviewProtalix BioTherapeutics, Inc. (NYSE: PLX) surprised to the upside with a strong quarter of sales for Elfabrio, generating revenues of over $14 million for the product in 2Q:26. The result vaulted total revenues to almost $20 million, which helped tip earnings into positive territory. Elelyso revenues were also ahead of our estimates, rising 3%.Other positive news since th...

Will Pfizers Non-COVID Portfolio Drive Its Next Phase of Growth?

PFEs non-COVID products are gaining momentum, with launches, acquisitions and a pipeline aimed at driving growth from 2029 onward.

Valneva Aktie: Borreliose-Impfstoff als großer Wachstumstreiber - Kursziel 12 Dollar

New York (www.aktiencheck.de) - Valneva-Aktienanalyse von TD Cowen:Die Analysten von TD Cowen nehmen die Coverage für die Aktie von Valneva SE (ISIN: FR0004056851, WKN: A0MVJZ, Ticker-Symbol: AYJ, Euronext Paris-Symbol: VLA) mit dem Rating "buy" und dem Kursziel von 12 USD auf.Das Basis-Impfstoffgeschäft des Unternehmens biete Schutz vor Abwärtsrisiken, während LB6V ein "risikoreduzierter" Lyme-Borreliose-Impfstoff sei, der durch eine validierte biologische Grundlage und die regulatorische E...

Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock

This problem has a solution, and Pfizer is implementing it.

Pfizers Earnings Have Declined 58% This Year. Is a Dividend Cut Around the Corner?

The stocks 6.4% yield is attractive, but it comes with risk.

Pfizer Aktie: Milliarden-Abschreibungen und verschärftes Sparprogramm

Frankfurt (www.aktiencheck.de) - Pfizer-Aktienanalyse von XTB:Der US-Pharmagigant Pfizer Inc. (ISIN: US7170811035, WKN: 852009, Ticker-Symbol: PFE, NYSE-Symbol: PFE) hat mit seinen Ergebnissen für das zweite Quartal 2026 ein klares Signal an den Markt gesendet, so die Experten von XTB. Mit einem überraschend starken Umsatz von rund 15 Milliarden US-Dollar habe der Konzern die Erwartungen der Analysten übertroffen und gezeigt, dass die operative Trendwende nach den massiven Rückgängen im COVI...

Berenberg belässt Pfizer auf Hold - Ziel 25 Dollar

HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Pfizer nach Quartalszahlen auf "Hold" mit einem Kursziel von 25 US-Dollar belassen. Mit disziplinierter Umsetzung von Managementzielen und gezielten Investitionen in die Pipeline soll der Umsatz 2028 bis 2033 laut dem Pharmakonzern im hohen einstelligen Bereich wachsen. [mehr]

Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs

Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously.

Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis

Pfizer beat Wall Street estimates for ?second-quarter profit on Tuesday, driven by strong demand for ?its blood thinner, Eliquis.

Pfizer raises revenue outlook after quarterly earnings top estimates

Pfizer Inc (NYSE:PFE, XETRA:PFE) beat Wall Street expectations for its second-quarter 2026 results and raised the midpoint of its full-year revenue...

Pfizers Stock Has Been a Dud Over the Past 5 Years, but Is It Still Worth Buying for Its 6.9% Yield?

The stocks yield is more than six times the S&P 500 average.

Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?

Amgen, Pfizer, Eli Lilly, Merck and Novo Nordisk are set to report Q2 results this week after a strong start for pharma earnings. Which names could beat forecasts?

Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock?

There is more to this stock than meets the eye.

Pfizers Bear Case Is Breaking

Pfizer Stock Ahead of Q2 Earnings: To Buy or Not to Buy?

Pfizer heads into Q2 earnings with expectations for growth in key products, COVID headwinds, and guidance updates that could shape its outlook.

Schutz vor dem KI-Rücksetzer: Jefferies rät zu Dividenden-Schwergewichten - diese Aktien stechen heraus

Jefferies rät zu Aktien mit niedriger Volatilität und hoher DividendeProcter & Gamble, Pfizer, KeyCorp und Simon Property Group stehen im FokusAnsatz soll vor einer möglichen Korrektur der KI-Rally schützen

Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pfizer: Calling The Bottom - The Patent Cliff Is Real, But The Valuation Has Fallen Too Far

Pfizers Dividend Yield Looks Almost Too Good. Heres Why Management Isnt Worried.

Pfizer has a 6.8% yield at a time when the markets yield is roughly 1%: Is there something wrong?

Is Pfizers 7% Dividend Yield Too Good to Be True? Heres the Straight Answer

Income seekers shouldnt give up on the stock yet.

Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know

In the latest trading session, Pfizer (PFE) closed at $24.75, marking a -1.2% move from the previous day.

Looking for Cheap Income Stocks? Why Pfizer Belongs on Your Shortlist Right Now

Pfizer is a highly respected drug company facing normal industry headwinds.

Heres How Pfizers Oncology Growth Story Looks Ahead of Q2 Results

PFEs oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates may offset declines in older therapies.

Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried?

The pharma giants yield of around 7.1% is more than six times the S&P 500 average.

CEO Chat with Dr. Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics

NASDAQ: LABTDavid Bautz, PhD: Welcome to our next episode in our CEO Chat series. My name is David Bautz. Im a senior biotechnology analyst here at Zacks Small Cap Research. Joining me today is Dr. Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics (NASDAQ: LABT). Lakewood-Amedex is developing the Bisphosphocin® class of antimicrobials to address unmet needs in the treatment of acute and chronic infectious diseases. We recently initiated coverage of Lakewood-Amedex with a $12 valuation. He...

Pfizer Aktie: Droht jetzt neuer Gegenwind?

Charlotte (www.aktiencheck.de) - Pfizer-Aktienanalyse der Bank of America (BofA):BofA habe das Kursziel für die Aktie von Pfizer Inc. (ISIN: US7170811035, WKN: 852009, Ticker-Symbol: PFE, NYSE-Symbol: PFE) von 27 auf 26 USD gesenkt und das "neutral"-Rating bestätigt. Nach Einschätzung der Analysten dürften die Ergebnisse für das zweite Quartal zeigen, dass Pharmakonzerne mit hochwertigen Medikamentenportfolios und nachhaltigen Wachstumstreibern weiterhin eine stärkere Entwicklung aufweisen wür...

FDA Expands MRK & PFEs Keytruda-Padcev Combo Use in Bladder Cancer

Mercks Keytruda in combination with Pfizers Padcev wins FDA nod for expanded use in muscle-invasive bladder cancer, regardless of cisplatin eligibility.

Pfizer: The AI Hedge That Pays You To Stay Defensive

Pfizer remains an undervalued diversification play, underperforming the benchmark but increasing 2% since prior coverage. Learn why PFE stock is a strong buy.

Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market?

So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off.